StreetAlpha.app
Home › Stocks › ZBIO

Zenas BioPharma, Inc. (ZBIO)

Healthcare
$23.85
▼ −4.75%
LAST CLOSE · NOV 20

Zenas BioPharma develops immune system drugs for autoimmune diseases, led by the antibody candidate obexelimab. It last closed at $23.85 on Nov 20, down 4.75% on the day. The next earnings report for ZBIO is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, ZBIO reported EPS of -$1.65 on revenue of $10.0M. Over its last 8 reports the stock moved an average of 13.4% the session after earnings. Over the last 12 months ZBIO insiders bought $11.4M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ZBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZBIO.

Key Stats

Last 12 months
Results
Revenue
$11.0M
−26.7% vs a year ago
Net income
−$541.8M
−4925.5% margin
EPS (diluted)
−$10.08
−173.7% vs a year ago
Free cash flow
−$242.8M
−2207.6% margin
Valuation
Market cap
$1.6B
67.8M shares
P/E
–
No P/E while losing money
Price to sales
147.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$177.8M
At Sep 30
Debt
$223.2M
At Sep 30
Shareholder equity
$212.3M
Shares outstanding
67.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $50.0M$50.0MFY2023FY2024: $5.0M$5.0MFY2024FY2025: $10.0M$10.0MFY2025

From ZBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
-$1.65
Quarter ended Sep 2026
Year ago EPS
-$1.22
Same quarter last year
Revenue
$10.0M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $16.94Dec '24Mar 2025: -$0.80Mar '25Jun 2025: -$1.25Jun '25Sep 2025: -$1.22Sep '25Dec 2025: -$5.17Dec '25Mar 2026: -$1.46Mar '26Jun 2026: -$1.77Jun '26Sep 2026: -$1.65Sep '26Latest -$1.65
Revenue by quarter
Dec 2024: $5.0MDec '24Mar 2025: $10.0MMar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Jun 2026: $1.0MJun '26Sep 2026: $10.0MSep '26Latest $10.0M
How ZBIO moved after its last 8 reports
Average move the session after a report ±13.4%
Nov 5, 2026Time not announced−8.9%
Aug 13, 2026Time not announced−6.7%
May 13, 2026Time not announced+4.0%
Mar 16, 2026Time not announced−3.4%
Jan 5, 2026Time not announced−51.9%
Nov 12, 2025Time not announced+1.7%
Oct 8, 2025Time not announced+24.2%
Aug 12, 2025Time not announced+6.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZBIO

Technical Analysis

ZBIO · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 16% below its 20 day and 17% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $23.21, and the nearest resistance the Pivot at $24.42.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.4%/day
Key levels
$44.6052 week high+87.0%
$29.52100 day average+23.8%
$29.23Swing high (Oct 1)+22.6%
$27.9950 day average+17.4%
$27.5820 day average+15.6%
$25.51200 day average+7.0%
$25.07Pivot R1+5.1%
$24.42Pivot+2.4%
$23.85Last close
$23.21Pivot S1−2.7%
$16.90Swing low (Jun 2)−29.1%
$13.5052 week low−43.4%
Indicators
RSI (14)33.07Weak, oversold below 30Neutral
MACD-0.58Below its signal lineBearish
Stochastic6.0Near the bottom of its rangeOversold
ADX (14)14.5No clear trend
Williams %R-98.9Oversold below −80, overbought above −20Oversold
CCI (20)-274.6Oversold below −100, overbought above 100Oversold
Rate of change−15.6%Change over 10 sessionsBearish
ATR (14)$1.77Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZBIO

What happened before

See how ZBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for ZBIOHow many large options trades hit ZBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ZBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲88 buying vs 48 selling
  • ▲Held by funds +10.1 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153145+5.5%
In funds' top 1078−12.5%
Held by funds100.5%90.3%+10.1 pts
New / increased20 / 6827 / 60+1.1%
Reduced / sold out35 / 1339 / 25−25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$11.4M10 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $6.7M between Mar 30 and Apr 29.
2026-01 bought $1.6M2026-02 bought $2.1M2026-03 bought $5.6M2026-04 bought $1.1M2026-05 bought $1.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 18Leon O Moulder JrCEOBuy60,000$16.88$1.0M
Apr 29Leon O Moulder JrCEOBuy60,000$17.79$1.1M
Mar 31Hongbo LuDirectorBuy3,768$18.63$70K
Mar 31Fairmount Funds Management LLCDirectorBuy150,000$20.00$3.0M
Mar 31Leon O Moulder JrCEOBuy54,000$18.91$1.0M
Mar 31Hongbo LuDirectorBuy75,000$20.00$1.5M
Every insider buy and sale for ZBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZBIO insider trades →

From SEC Form 4 filings by ZBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZBIO is in one of them and how their past ZBIO trades turned out.

ZBIO in the AI portfolios
Loading…

ZBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZBIO in an article yet. Here's the latest on the wider market.

ZBIO in the news

About Zenas BioPharma

Zenas BioPharma is a biopharmaceutical company based in Waltham, Massachusetts, that develops drugs targeting the immune system to treat autoimmune diseases. Its lead candidate, obexelimab, is an antibody designed to calm B cells, which play a role in conditions such as IgG4-related disease, relapsing multiple sclerosis and lupus. The company is also developing orelabrutinib, an oral drug for progressive forms of multiple sclerosis, along with several earlier stage candidates. It has no approved products and does not sell drugs today, so its intended customers are patients with autoimmune diseases and the doctors who treat them.

Headquarters
Waltham, MA